FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2509930573> ?p ?o ?g. }

• W2509930573 endingPage "1163.e2" @default.
• W2509930573 startingPage "1155" @default.
• W2509930573 abstract "Background & AimsConventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC.MethodsFrom October 2009 through October 2015, we reviewed patients with HCC of all Barcelona Clinic Liver Cancer (BCLC) stages for eligibility. Of these, 179 patients with BCLC stages A or B met our enrollment criteria and were candidates for cTACE or Y90 therapy. Patients were assigned randomly to groups that received Y90 therapy (n = 24; 50% Child–Pugh A) or cTACE (n = 21; 71% Child–Pugh A). The primary outcome was time to progression (TTP), evaluated by intention-to-treat analysis. Secondary outcomes included safety, rate of response (based on tumor size and necrosis criteria), and Kaplan–Meier survival time. We performed inverse probability of censoring weighting and competing risk analyses.ResultsPatients in the Y90 radioembolization group had significant longer median TTP (>26 mo) than patients in the cTACE group (6.8 mo; P = .0012) (hazard ratio, 0.122; 95% confidence interval [CI], 0.027–0.557; P = .007). This was confirmed by competing risk and inverse probability of censoring weighting analyses accounting for transplantation or death. A significantly greater proportion of patients in the cTACE group developed diarrhea (21%) than in the Y90 group (0%; P = .031) or hypoalbuminemia (58% in the cTACE group vs 4% in the Y90 group; P < .001). Similar proportions of patients in each group had a response to therapy, marked by necrosis (74% in the cTACE group vs 87% in the Y90 group) (P = .433). The median survival time, censored to liver transplantation, was 17.7 months for the cTACE group (95% CI, 8.3–not calculable) vs 18.6 months for the Y90 group (95% CI, 7.4–32.5) (P = .99).ConclusionsIn a randomized phase 2 study of patients with HCC of BCLC stages A or B, we found Y90 radioembolization to provide significantly longer TTP than cTACE. Y90 radioembolization provides better tumor control and could reduce drop-out from transplant waitlists. ClinicalTrials.gov no. NCT00956930. Conventional transarterial chemoembolization (cTACE) is used to treat patients with hepatocellular carcinoma (HCC). Radioembolization is a minimally invasive procedure that involves implantation of radioactive micron-sized particles loaded with yttrium-90 (Y90) inside the blood vessels that supply a tumor. We performed a randomized, phase 2 study to compare the effects of cTACE and Y90 radioembolization in patients with HCC. From October 2009 through October 2015, we reviewed patients with HCC of all Barcelona Clinic Liver Cancer (BCLC) stages for eligibility. Of these, 179 patients with BCLC stages A or B met our enrollment criteria and were candidates for cTACE or Y90 therapy. Patients were assigned randomly to groups that received Y90 therapy (n = 24; 50% Child–Pugh A) or cTACE (n = 21; 71% Child–Pugh A). The primary outcome was time to progression (TTP), evaluated by intention-to-treat analysis. Secondary outcomes included safety, rate of response (based on tumor size and necrosis criteria), and Kaplan–Meier survival time. We performed inverse probability of censoring weighting and competing risk analyses. Patients in the Y90 radioembolization group had significant longer median TTP (>26 mo) than patients in the cTACE group (6.8 mo; P = .0012) (hazard ratio, 0.122; 95% confidence interval [CI], 0.027–0.557; P = .007). This was confirmed by competing risk and inverse probability of censoring weighting analyses accounting for transplantation or death. A significantly greater proportion of patients in the cTACE group developed diarrhea (21%) than in the Y90 group (0%; P = .031) or hypoalbuminemia (58% in the cTACE group vs 4% in the Y90 group; P < .001). Similar proportions of patients in each group had a response to therapy, marked by necrosis (74% in the cTACE group vs 87% in the Y90 group) (P = .433). The median survival time, censored to liver transplantation, was 17.7 months for the cTACE group (95% CI, 8.3–not calculable) vs 18.6 months for the Y90 group (95% CI, 7.4–32.5) (P = .99). In a randomized phase 2 study of patients with HCC of BCLC stages A or B, we found Y90 radioembolization to provide significantly longer TTP than cTACE. Y90 radioembolization provides better tumor control and could reduce drop-out from transplant waitlists. ClinicalTrials.gov no. NCT00956930." @default.
• W2509930573 created "2016-09-16" @default.
• W2509930573 creator A5009973828 @default.
• W2509930573 creator A5011003738 @default.
• W2509930573 creator A5028184921 @default.
• W2509930573 creator A5029706633 @default.
• W2509930573 creator A5033464248 @default.
• W2509930573 creator A5034174603 @default.
• W2509930573 creator A5034975837 @default.
• W2509930573 creator A5036972230 @default.
• W2509930573 creator A5044862107 @default.
• W2509930573 creator A5059298173 @default.
• W2509930573 creator A5060796651 @default.
• W2509930573 creator A5066524469 @default.
• W2509930573 creator A5071616102 @default.
• W2509930573 creator A5073037737 @default.
• W2509930573 creator A5082906150 @default.
• W2509930573 creator A5085978876 @default.
• W2509930573 creator A5087536545 @default.
• W2509930573 creator A5090043054 @default.
• W2509930573 creator A5090639130 @default.
• W2509930573 date "2016-12-01" @default.
• W2509930573 modified "2023-10-17" @default.
• W2509930573 title "Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma" @default.
• W2509930573 cites W1506777089 @default.
• W2509930573 cites W1859381337 @default.
• W2509930573 cites W1971837077 @default.
• W2509930573 cites W1973617793 @default.
• W2509930573 cites W1975154077 @default.
• W2509930573 cites W1979533557 @default.
• W2509930573 cites W1982153769 @default.
• W2509930573 cites W1984869178 @default.
• W2509930573 cites W1985503253 @default.
• W2509930573 cites W1994290810 @default.
• W2509930573 cites W1996229105 @default.
• W2509930573 cites W2007593124 @default.
• W2509930573 cites W2008557562 @default.
• W2509930573 cites W2046516248 @default.
• W2509930573 cites W2052552898 @default.
• W2509930573 cites W2071618269 @default.
• W2509930573 cites W2073140442 @default.
• W2509930573 cites W2077349751 @default.
• W2509930573 cites W2081176013 @default.
• W2509930573 cites W2082466657 @default.
• W2509930573 cites W2104278420 @default.
• W2509930573 cites W2110802064 @default.
• W2509930573 cites W2125763116 @default.
• W2509930573 cites W2125879455 @default.
• W2509930573 cites W2128125049 @default.
• W2509930573 cites W2148096215 @default.
• W2509930573 cites W2150325589 @default.
• W2509930573 cites W2153935627 @default.
• W2509930573 cites W2163403599 @default.
• W2509930573 cites W2165933819 @default.
• W2509930573 cites W2169874604 @default.
• W2509930573 cites W2286222994 @default.
• W2509930573 cites W2300346501 @default.
• W2509930573 cites W2433187988 @default.
• W2509930573 cites W2917837889 @default.
• W2509930573 cites W4245784696 @default.
• W2509930573 doi "https://doi.org/10.1053/j.gastro.2016.08.029" @default.
• W2509930573 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5124387" @default.
• W2509930573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27575820" @default.
• W2509930573 hasPublicationYear "2016" @default.
• W2509930573 type Work @default.
• W2509930573 sameAs 2509930573 @default.
• W2509930573 citedByCount "440" @default.
• W2509930573 countsByYear W25099305732016 @default.
• W2509930573 countsByYear W25099305732017 @default.
• W2509930573 countsByYear W25099305732018 @default.
• W2509930573 countsByYear W25099305732019 @default.
• W2509930573 countsByYear W25099305732020 @default.
• W2509930573 countsByYear W25099305732021 @default.
• W2509930573 countsByYear W25099305732022 @default.
• W2509930573 countsByYear W25099305732023 @default.
• W2509930573 crossrefType "journal-article" @default.
• W2509930573 hasAuthorship W2509930573A5009973828 @default.
• W2509930573 hasAuthorship W2509930573A5011003738 @default.
• W2509930573 hasAuthorship W2509930573A5028184921 @default.
• W2509930573 hasAuthorship W2509930573A5029706633 @default.
• W2509930573 hasAuthorship W2509930573A5033464248 @default.
• W2509930573 hasAuthorship W2509930573A5034174603 @default.
• W2509930573 hasAuthorship W2509930573A5034975837 @default.
• W2509930573 hasAuthorship W2509930573A5036972230 @default.
• W2509930573 hasAuthorship W2509930573A5044862107 @default.
• W2509930573 hasAuthorship W2509930573A5059298173 @default.
• W2509930573 hasAuthorship W2509930573A5060796651 @default.
• W2509930573 hasAuthorship W2509930573A5066524469 @default.
• W2509930573 hasAuthorship W2509930573A5071616102 @default.
• W2509930573 hasAuthorship W2509930573A5073037737 @default.
• W2509930573 hasAuthorship W2509930573A5082906150 @default.
• W2509930573 hasAuthorship W2509930573A5085978876 @default.
• W2509930573 hasAuthorship W2509930573A5087536545 @default.
• W2509930573 hasAuthorship W2509930573A5090043054 @default.
• W2509930573 hasAuthorship W2509930573A5090639130 @default.
• W2509930573 hasBestOaLocation W25099305731 @default.
• W2509930573 hasConcept C126322002 @default.
• W2509930573 hasConcept C141071460 @default.

• next